A large pharmaceutical company asked Covance to support their studies for a diabetes Phase III program specifically to register a drug to treat Type 2 Diabetes.
Understanding the Challenge
Covance needed to recruit 2,700 patients across the world in the extremely competitive arena of diabetes studies. In addition, the sponsor wanted to get all the sites up and running as quickly as possible while employing cost-effective measures.
Read how Covance utilized its rich central laboratory services database and helped the sponsor achieve first patient in (FPI) ahead of schedule for all studies in the program and beat historical industry performance across a number of key metrics.